Warner-Lambert/RPR sparfloxacin agreement
Warner-Lambert and Rhone-Poulenc Rorer will co-promote the oral quinolone antibiotic in the U.S. and Canada under a development agreement announced April 1. Warner-Lambert licensed sparfloxacin from Japan's Dainippon in 1989. Rhone-Poulenc Rorer will conduct clinical studies of the product, which is expected soon to enter Phase III for community acquired infections and is already in Phase III for skin infections, pneumonia, bronchitis and complicated urinary tract infections. RPR already has an agreement with Dainippon to develop and market sparfloxacin in Europe. Warner-Lambert will continue its Phase I studies of sparfloxacin for Mycobacterium avium complex in AIDS patients, an indication not included in the co-development deal ("The Pink Sheet" March 23, T&G-5).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth